Taper Or Abrupt Steroid Stop: TOASSTtrial

Inclusion Criteria:

• Informed Consent as documented by signature (Appendix Informed Consent Form)

• Age ≥ 18 years

• Daily glucocorticoid dose ≥ 7.5 mg prednisone-equivalent at the time of inclusion

• Therapy over ≥ 28 days, ≥ 7.5 mg average daily dose, with a cumulativeglucocorticoid dose ≥ 420 mg prednisone-equivalent prior to inclusion

• Tapering not or no longer mandatory to treat underlying disease

Exclusion Criteria:

• Primary adrenal failure

• Treatment with systemic depot glucocorticoids (e.g. intramuscular, epidural)

• Incapability to administer glucocorticoid cover treatment in situations of stress

• Inability or unwillingness to provide informed consent

• Women who are pregnant or breast feeding,

• Intention to become pregnant during the course of the study,

• Lack of safe contraception, defined as: Female participants of childbearingpotential, not using and not willing to continue using a medically reliable methodof contraception for the entire study duration, such as oral, injectable, orimplantable contraceptives, or intrauterine contraceptive devices, or who are notusing any other method considered sufficiently reliable by the investigator inindividual cases.

• Known or suspected non-compliance

• Inability to follow the procedures of the study, e.g. due to language problems,psychological disorders, dementia, etc. of the participant,

• Participation in another study with investigational drug within the 30 dayspreceding and during the present study,

• Previous enrolment into the current study,

• Enrolment of the investigator, his/her family members, employees and other dependentpersons